CytomX Therapeutics (CTMX) EBIT (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly EBIT came in at -$19.7 million in Q1 2026, down 186.96% YoY from $22.6 million in Q1 2025, and up 29.57% on a QoQ basis from -$27.9 million in Q4 2025.
CytomX Therapeutics (CTMX) EBIT (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of EBIT data on file, last reported at -$19.7 million in Q1 2026.
- Quarterly EBIT fell 186.96% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.7 million (down 279.81% YoY) and the FY2025 annual result came in at -$22.4 million, down 189.47% from the prior year.
- EBIT rose to -$19.7 million in Q1 2026, from -$27.9 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $22.6 million in Q1 2025 to a low of -$32.1 million in Q1 2022.
- A 5-year average of -$7.3 million and a median of -$5.7 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT surged 3017.33% — and 2025, when it tumbled 483.56%.
- Tracing CTMX's EBIT over 5 years: stood at -$9.5 million in 2022, then jumped by 93.63% to -$606000.0 in 2023, then surged by 3017.33% to $17.7 million in 2024, then slumped by 258.0% to -$27.9 million in 2025, then climbed by 29.57% to -$19.7 million in 2026.
- The last three EBIT figures came in at -$19.7 million (Q1 2026), -$27.9 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | -23.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.78 Mn |
| Mar 31, 2026 | -19.67 Mn |
| Dec 31, 2025 | -27.93 Mn |
| Sep 30, 2025 | -15.77 Mn |
| Jun 30, 2025 | -1.29 Mn |
| Mar 31, 2025 | 22.62 Mn |
| Dec 31, 2024 | 17.68 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | -8.45 Mn |
| Mar 31, 2024 | 11.66 Mn |
| Dec 31, 2023 | -606,000.00 |
| Sep 30, 2023 | 3.12 Mn |
| Jun 30, 2023 | -3.35 Mn |
| Mar 31, 2023 | -5.65 Mn |
| Dec 31, 2022 | -9.51 Mn |
| Sep 30, 2022 | -29.71 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | -32.06 Mn |
| Dec 31, 2021 | -34.90 Mn |
| Sep 30, 2021 | -31.04 Mn |